KONEXElectrical Equipment244880

Nanoomtech

₩1,770▼ 1.50%2026-10-02 close

Market Cap

₩8.9B

Turnover

₩65,721

Volume

38 shares

Shares out.

PER

—

PBR

—

EPS

—

Dividend Yield

5.65%

PER, PBR and dividend yield are calculated from the latest confirmed results (EPS, BPS, dividend per share) and the current share price · Prices as of the 2026-10-02 close

Report overview

An AED Niche Champion Goes AI

Nanoom Tech, a KONEX-listed AED specialist that pioneered Korea's domestically manufactured defibrillator, is testing whether an AI-powered ECG algorithm product can extend a revenue trajectory that already more than doubled between 2020 and 2023.

1
Pioneer of Korean-Made AED: Co-developed with GIST to achieve domestic AED production, holding 6 related patents
2
Revenue More Than Doubled: From approximately KRW 8 billion (2020) to ~KRW 18 billion (2023), per September 2024 media reporting
3
AI Product Pipeline: AI-based ECG algorithm AED targeted for government procurement excellence listing; completion status requires DART verification
4
40-Country Export Footprint: 65,000+ domestic installed locations; exports to 40 countries including EU and the Americas
5
Near-Zero Market Liquidity: Daily trading value of approximately KRW 1.95 million (June 7, 2026), severely restricting investability

Business structure

Nanoom Tech is a Gwangju-based medical device company whose core business is the manufacturing and distribution of Automated External Defibrillators (AEDs).

Its flagship products—marketed under the 'HeartKeeper' and 'ReHeart' brands—were co-developed with GIST (Gwangju Institute of Science and Technology) as Korea's first domestically manufactured AEDs; the company currently holds 6 AED-related patents.

Domestically, the company supplies more than 65,000 locations including public institutions, banks, schools, and hospitals, with government procurement via the narajangter platform serving as the primary domestic revenue channel.

Consumables such as electrode pads and batteries form a complementary recurring revenue stream whose structural volume grows in line with the expanding installed base.

Internationally, the company has established itself as a global niche player by exporting to 40 countries including EU member states and the Americas, consistently acquiring new overseas medical device certifications each year.

In competitive terms, Nanoom Tech contends with global AED leaders such as Philips and ZOLL, differentiating through the pricing competitiveness of its domestically manufactured products and its qualification for Korean public procurement requirements.

Per FnGuide company data, the company has completed development of a new low-power AED featuring a patented AI-based ECG analysis algorithm and pursued government procurement excellence listing, representing the leading edge of its product portfolio upgrade.

An outdoor AED product line is also being expanded to address installation segments beyond traditional indoor venues. While the company operates an in-house R&D center, its approximately 30-person workforce imposes inherent resource constraints alongside its focused technical mission.

Recent trends

According to a September 2024 Moodilbo (regional media) report, Nanoom Tech's annual revenue grew from approximately KRW 8 billion in 2020 to approximately KRW 18 billion in 2023—more than doubling in three years.

This top-line expansion is primarily attributed to rising societal awareness of cardiac emergency response and progressive tightening of AED mandatory installation regulations.

The company reports contributing to 92 documented domestic life-saving incidents over the past decade based on internally tracked cases, which has supported product credibility and brand recognition.

Per FnGuide company data, a new AED featuring a patented AI-based ECG algorithm was targeted for H1 2025 government procurement excellence listing; however, the final outcome of this registration process requires verification against the latest DART filings.

On the market side, the share price rose 8.27% to KRW 1,950 as of June 7, 2026, but the day's trading value of approximately KRW 1.95 million renders this price movement statistically low-significance and unrepresentative of market consensus.

KONEX structural characteristics restrict institutional and foreign investor participation, and lower mandatory disclosure frequency limits real-time financial monitoring relative to KOSDAQ or KOSPI.

FnGuide lists December 2024 (annual) as the latest fiscal reference period, but specific financial figures require verification against official DART source documents. Overall, the revenue growth trajectory appears broadly positive, though the KONEX micro-cap nature remains a meaningful constraint on analytical rigor.

Outlook

In the near term, whether the AI-powered ECG algorithm AED achieves government procurement excellence listing—and the associated impact on public procurement volumes—will be the critical swing factor for 2025–2026 performance.

Domestic policy trajectory, with progressively expanding AED mandatory installation requirements, structurally underpins medium-term Korea revenue.

Internationally, pursuing additional medical device certifications beyond the existing 40-country footprint—particularly in emerging markets—could serve as a meaningful medium-term revenue diversification catalyst.

The naturally growing consumables replacement cycle linked to an expanding installed base represents a structural advantage for recurring revenue stability over the medium-to-long term.

Over the longer term, the company's capital strategy—including whether to seek an uplist to KOSDAQ or raise external growth capital—will be a binding constraint on scaling the business.

The global AED market is expected to benefit from aging demographics, rising cardiovascular disease, and public health infrastructure investment, but material brand, distribution, and headcount scaling is a prerequisite for Nanoom Tech to capture a significant share of this growth.

The trajectory of product evolution toward smart AEDs with integrated AI and IoT capabilities will also be a defining factor in long-term competitive positioning.

Bull factors

AI ECG Product Targets Procurement Excellence Catalyst

Per FnGuide company data, a new low-power AED featuring a patented AI-based ECG analysis algorithm was targeted for H1 2025 government procurement excellence listing on narajangter.

If successfully registered, this would structurally expand public institution procurement volumes, providing a direct near-term revenue catalyst. AI-based ECG analysis technology enhances product differentiation and is expected to strengthen marketing competitiveness in international markets as well.

The combination of patent registration and excellence product status should bolster brand credibility and improve order conversion rates.

Structural Domestic Demand Driven by Expanding AED Mandates

Korea's growing societal awareness of cardiac emergency response has been accompanied by a progressive expansion of mandatory AED installation requirements across public institutions and facilities, generating policy-driven structural demand growth.

As of September 2024 reporting, over 65,000 locations have been equipped domestically, and further mandate expansion would create recurring procurement opportunities for the company.

An expanding installed base naturally drives consumables (electrode pads, batteries) replacement demand, strengthening the recurring revenue component of the business. Policy-mandated demand is relatively less sensitive to economic cycles, lending greater visibility to the revenue trajectory.

40-Country Export Base as a Platform for Global Growth

Nanoom Tech has already established itself as a global niche player by exporting AEDs to 40 countries, consistently acquiring new overseas medical device certifications each year to expand into new markets.

The global AED market is expected to sustain medium-to-long-term growth driven by aging demographics and increasing cardiovascular disease prevalence. The cost competitiveness of Korean-manufactured AEDs can serve as a meaningful differentiator, particularly in emerging and middle-income country markets.

The fact that revenue more than doubled between 2020 and 2023 provides concrete evidence that the export expansion strategy has been translating into tangible results.

Bear factors

Structural Illiquidity of the KONEX Micro-Cap

With a daily trading value of approximately KRW 1.95 million as of June 7, 2026, the stock is effectively illiquid by any conventional standard.

KONEX's structural characteristics restrict institutional and foreign investor participation, widen bid-ask spreads, and heighten the risk of price distortion from concentrated, infrequent trading.

The absence of adequate liquidity inflates price volatility independent of underlying fundamentals and exacerbates information asymmetry risks for investors. This dynamic raises entry and exit costs, perpetuating a self-reinforcing cycle that deters institutional interest over the long term.

Scale and Brand Disadvantage Versus Global AED Leaders

Global AED leaders such as Philips and ZOLL possess materially larger R&D budgets, global distribution networks, and brand recognition compared to Nanoom Tech.

With a workforce of approximately 30 employees, the company faces structural constraints in multi-country localization, large-deal bidding, and simultaneous pursuit of multiple international certifications.

In developed markets, the entrenched positions of global brands mean that penetration and share gains require substantial time and capital investment. Even the AI-powered new product faces the risk of diminishing technological differentiation if global competitors rapidly commercialize comparable capabilities.

Revenue Concentration in Government Procurement

A significant portion of domestic revenue is understood to flow through government procurement channels including narajangter, directly exposing the top line to public budget volatility. Any reduction in AED procurement budgets or policy changes affecting AED mandates could result in immediate revenue impact.

Intensifying bid competition and downward pressure on contract award prices represent structural risks to operating margins even amid volume growth. Consumables demand is similarly contingent on institutional budget allocations, meaning replacement cycles could be delayed in fiscal austerity environments.

Risk factors

Macro Risk

A global economic slowdown could trigger reductions in government healthcare budgets and public AED installation spending, simultaneously pressuring both domestic and international revenue.

For the emerging market countries comprising a meaningful share of the 40-country export footprint, currency volatility and reduced purchasing power could negatively affect both unit pricing and demand volumes.

Tightening medical device regulations and evolving certification standards in major markets such as the US and EU impose additional compliance costs and timeline risks on export channels.

Rising protectionism and domestic-content preferences in public procurement could also unfavorably alter the competitive environment for Korean-made AEDs.

Sector Risk

Continuous new technology development by global AED manufacturers and intensifying price competition could make it increasingly difficult for Nanoom Tech to defend its market share positions.

If the technological paradigm shift toward smart AEDs with integrated AI and IoT capabilities accelerates, the competitive lifespan of the current product lineup could shorten materially.

Entry of new domestic competitors or increased direct participation by foreign players in Korea's public procurement market could rapidly reshape the competitive environment.

Delays in medical device regulatory approval and change assessment also introduce uncertainty into new product launch timelines, a sector-specific risk inherent to medical device businesses.

Company-Specific Risk

With approximately 30 employees, the departure of key R&D or sales personnel could immediately impair the company's product development pipeline and customer acquisition capabilities.

KONEX listing standards entail lower mandatory financial disclosure frequency and reduced regulatory oversight compared to KOSDAQ or KOSPI, limiting investors' ability to monitor the financial position in real time.

Any equity capital raise or external investment to fund growth carries inherent dilution risk for existing shareholders, and the impact of such events on the share price could be amplified by the micro-cap context.

The extremely small market capitalization creates structural vulnerability to abnormal price volatility, which could undermine the long-term investor confidence foundation.

Overall view

Nanoom Tech is a genuine growth company that has more than doubled its revenue between 2020 and 2023, underpinned by its pioneering position in Korea's domestically manufactured AED market; the AI ECG algorithm product pipeline and policy-driven structural demand from expanding AED mandates provide a credible medium-term growth narrative.

However, near-zero daily trading liquidity, limited KONEX financial disclosure frequency, and the scarcity of publicly available quantitative financial data make rigorous and reliable valuation highly challenging.

The scale gap versus global AED leaders, revenue concentration in government procurement, and small-organization vulnerability remain structural challenges that require ongoing management to deliver the long-term growth potential.

On balance, the positive social utility of the business model and the demonstrated revenue growth trajectory are offset by equally real investment accessibility constraints—supporting a 'Neutral' analytical stance.

This report is provided for informational purposes only and does not constitute investment advice; readers are strongly encouraged to verify the latest DART official filings and financial statements before making any investment decision.

Sources

Korea Exchange (KRX) — Prices · Market Cap · Volume
FSS electronic disclosure system (DART) — Financial statements · Dividend filings

Show 5 more articles and sources

Report written 2026-06-08 · Data as of 2026-06-05

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.